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Abstract
Objective: Genetic activation of the insulin signal-transducing kinase AKT2 causes syndromic hypoketotic 
hypoglycaemia without elevated insulin. Mosaic activating mutations in class 1A phospatidylinositol-3-kinase (PI3K), 
upstream from AKT2 in insulin signalling, are known to cause segmental overgrowth, but the metabolic consequences 
have not been systematically reported. We assess the metabolic phenotype of 22 patients with mosaic activating 
mutations affecting PI3K, thereby providing new insight into the metabolic function of this complex node in insulin 
signal transduction.
Methods: Three patients with megalencephaly, diffuse asymmetric overgrowth, hypoketotic, hypoinsulinaemic 
hypoglycaemia and no AKT2 mutation underwent further genetic, clinical and metabolic investigation. Signalling 
in dermal fibroblasts from one patient and efficacy of the mTOR inhibitor Sirolimus on pathway activation were 
examined. Finally, the metabolic profile of a cohort of 19 further patients with mosaic activating mutations in PI3K 
was assessed.
Results: In the first three patients, mosaic mutations in PIK3CA (p.Gly118Asp or p.Glu726Lys) or PIK3R2 (p.Gly373Arg) 
were found. In different tissue samples available from one patient, the PIK3CA p.Glu726Lys mutation was present 
at burdens from 24% to 42%, with the highest level in the liver. Dermal fibroblasts showed increased basal AKT 
phosphorylation which was potently suppressed by Sirolimus. Nineteen further patients with mosaic mutations in 
PIK3CA had neither clinical nor biochemical evidence of hypoglycaemia.
Conclusions: Mosaic mutations activating class 1A PI3K cause severe non-ketotic hypoglycaemia in a subset of patients, 
with the metabolic phenotype presumably related to the extent of mosaicism within the liver. mTOR or PI3K inhibitors 
offer the prospect for future therapy.
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Introduction
Transient neonatal hypoglycaemia is common, often 
precipitated by inadequate deposition of energy stores 
in utero and/or perinatal stress. In contrast, persisting 
hypoglycaemia is often caused by a genetic disorder, 
and may be insulin dependent or insulin independent 
(1, 2, 3). The former is usually caused by congenital 
hyperinsulinism (CHI), or occasionally extreme insulin 
resistance (4). CHI-related hypoglycaemia features 
suppressed plasma ketones and free fatty acids but 
detectable plasma insulin, while glucagon stimulation 
characteristically increases blood glucose by greater than 
30 mg/dL (5). Carbohydrate requirement to maintain 
euglycaemia in CHI is high, with intravenous glucose 
infusion rates usually exceeding 8 mg/kg/min in neonates 
and infants (2). Non-insulin-dependent hypoglycaemia 
may be caused by inherited metabolic diseases including 
glycogen storage or fatty acid oxidation disorders (6, 7).
We previously described a syndromic form of 
hypoglycaemia whose metabolic profile resembles 
CHI, yet in which neither insulin nor insulin-like 
molecules can be detected during hypoglycaemia (8). 
It is caused by the p.Glu17Lys mutation in the kinase 
AKT2, a critical mediator of insulin action (9). This 
mutation partly uncouples AKT2 activation from insulin-
stimulated phosphatidylinositol-3-kinase (PI3K) activity 
by permitting binding of AKT2 to the PI3K substrate 
PIP2 in addition to its product phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) (Fig.  1) (10). This results in 
low-level cellular responses mimicking the presence 
of insulin.
Activating mutations in other components of the 
PI3K/AKT pathway are common in cancer (11, 12), 
and in isolation, in mosaic form, cause segmental 
overgrowth (13, 14, 15). The most commonly mutated 
gene is PIK3CA, encoding the p110α catalytic subunit of 
PI3K (13). Mutations in other genes including PIK3R2, 
encoding the p85β regulatory subunit of PI3K, are also 
described (16). PIK3CA-associated overgrowth in mosaic 
syndromes is known to affect venous and lymphatic 
vessels, adipose tissue, bone, muscle and neural tissue. 
Notably, the timing and site of the mutation gives rise 
to different patterns within the body, ranging from very 
specific localised/focal forms to diffuse manifestations 
involving multiple tissues. Additionally, the strength of 
genetic activation may further determine the severity 
of tissue-specific symptoms, resulting in pronounced 
phenotypic variability of these disorders, potentially also 
affecting metabolic and/or endocrine tissues. PIK3R2 
mutations lead to Megalencephaly–Polymicrogyria–
Polydactyly–Hydrocephalus (MPPH) syndrome, which is 
predominantly characterised by brain overgrowth and 
neurological abnormalities; mutations are often germline 
rather than mosaic. To date, although PIK3CA has been 
proven in numerous genetic and pharmacological studies 
to be critical for the metabolic effects exerted by insulin, 
and despite scattered mentions of hypoglycaemia in 
MCAP (17, 18), the metabolic phenotype has not been 
examined in detail.
We now describe three patients with early-onset, 
severe, non-ketotic hypoglycaemia associated with 
segmental overgrowth and activating mutations 
in PIK3CA or PIK3R2, and assess the PI3K pathway 
dysregulation in vitro in patients’ fibroblasts. Furthermore, 
we systematically survey the metabolic profile of a cohort 
of patients with mosaic PI3K activation ascertained 
through segmental overgrowth.
Figure 1
Schematic overview of INSR/PI3K/AKT 
signalling, showing known monogenic 
disorders. Asterisks (*) denote mutations 
described in this report. GoF, gain of 
function; LoF, loss of function.
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Subjects and methods
Cohort studied and ethical approval
Informed consent was obtained from all participants, 
research was approved by relevant research ethics 
committees, and the study was performed in accordance 
with the Declaration of Helsinki. For the cohort analysis, 
all patients with mosaic activating PIK3CA mutations from 
a study of segmental overgrowth for whom metabolic 
data were available were also assessed, encompassing 
volunteers with diagnoses of CLOVES (Congenital 
lipomatous overgrowth with vascular, epidermal, and 
skeletal anomalies) syndrome (OMIM #612918) (19), 
Klippel–Trenaunay (KT) syndrome (OMIM #149000) 
(20), Fibroadipose hyperplasia (13), macrodactyly or 
primary muscle overgrowth (21) or Megalencephaly–
Capillary Malformation (MCAP) (OMIM #602501) (22). 
Biochemical evaluations were performed in accredited 
diagnostic laboratories.
Genetic studies
For Sanger sequencing, exons and flanking regions 
were PCR amplified before sequencing using ABI’s 
BigDye Terminator Mix, purification using AgenCount 
AMPure Beads, capillary electrophoresis and analysis 
using Sequencher software (GeneCodes). Exome-
wide sequencing for P1 and parents was performed 
and analysed as previously described (23). PIK3CA 
p.Glu726Lys mutation burden was determined by 
custom-designed fluorescence-based restriction fragment 
assay (as described in Supplementary Online Material, see 
section on supplementary data given at the end of this 
article). P3 salivary DNA was sequenced using a custom 
panel of overgrowth-related genes on an Illumina MiSeq 
platform with preceding target enrichment. Further 
method and details are described in the Supplementary 
Online Material.
Cellular studies
Dermal fibroblasts were cultured from punch biopsies 
and maintained in DMEM supplemented with 10% Foetal 
Bovine Serum (FBS) containing 100 U/mL Penicillin, 
100 µg/mL Streptomycin and 4 mM l-Glutamine (all 
Sigma). For serum starvation, FBS was substituted by 0.5% 
Bovine serum albumin (Sigma). For signalling studies, 
fibroblasts were grown to confluence and washed twice 
with PBS before serum starvation for 24 h. Sirolimus (Sigma) 
was diluted in DMSO to 10 μM. Cells were pre-treated with 
Sirolimus or DMSO for 48 h prior to continued treatment 
during serum starvation. Cells were frozen in liquid 
nitrogen and stored at −80°C until processing.
AKT phosphorylation was determined using ELISAs for 
pThr308/309 and pSer473/474 (eBiosciences #85-86044 
& #85-86042) according to manufacturer’s instructions. 
Protein quantification was performed by DC Protein 
assay (BioRad). For immunoblotting, lysates were resolved 
by electrophoresis on 8% Bis-Tris gels (NuPage, Thermo 
Fisher) before transfer onto nitrocellulose membranes 
using the iBlot system (Life Technologies). Membranes 
were blocked in 4% BSA/TBST prior to primary antibody 
exposure for 16 h. Following the addition of secondary 
antibodies, blots were imaged on a BioRad ChemiDoc. The 
following antibodies were used: anti-calnexin (AbCam 
#22595), anti-AKT(1/2/3) (CST #9272) and anti-rabbit 
HRP conjugate (CST #7074). ImageLab software (BioRad) 
was used to determine band intensity.
Statistical analysis
Statistical analysis was undertaken using GraphPad Prism 
v.6. Log transformation was performed prior to analysis 
as the D’Agostino–Pearson test showed non-normal 
distribution of results. One-way analysis of variance 
(ANOVA) was undertaken followed by Dunnett’s test for 
comparison of patient against control cells.
Results
Clinical histories
Clinical features of patients 1–3 are summarised in 
Table 1. Patient 1 (P1) was born at 34 weeks to healthy, 
non-consanguineous white German parents after 
polyhydramnios and macrocephaly were noted in utero. 
Her birthweight was 3230 g (+2.0 s.d.), length 52 cm 
(+1.5 s.d.) and head circumference 37.5 cm (+2.3 s.d.). 
Generalized muscle hypotonia, hyperaemia of the face, a 
dorsal haemangioma and dysmorphic features including 
diastasis recti, syndactyly, short limbs and a ‘chubby’ 
appearance were noted at birth (Fig. 2A and B).
Recurrent hypoglycaemia was observed on day 1. On 
repeated evaluations, suppressed ketones, undetectable 
insulin and low free fatty acids were found concomitantly 
with blood glucose below 2.5 mmol/L. Growth hormone 
and cortisol rose in response to hypoglycaemia, 
while plasma amino acids, urinary organic acids and 
acylcarnitine profile were normal. There was neither 
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clinical nor biochemical evidence of glycogen storage 
diseases. Intravenous glucose requirement to maintain 
euglycaemia in the neonatal period was consistently 
below 8 mg/kg/min. Fasting tolerance in infancy peaked 
at 3 h before hypoglycaemia occurred, and management 
was based on frequent starch-enriched meals. Within the 
first months of life, poor oral intake led to placement of a 
percutaneous gastric (PEG) tube.
Diazoxide at up to 7.5 mg/kg/day for 2 weeks at the 
age of 1 year produced no benefit. Octreotide was tried 
once (5 µg/kg s.c.), and increased blood glucose from 1.8 
to 5.0 mmol/L within 30 min, but was discontinued due 
to flushing. Glucagon (1 mg s.c.) elicited a modest glucose 
response during hypoglycaemia (1.9–2.2 mmol/L within 
30 min); however, this was at a time of hepatopathy, 
evidenced by elevated liver transaminases (ALT 99 U/L, 
AST 183 U/L) and γGT (762 U/L). Liver biopsy, described 
in detail in Supplementary Online Material, did not reveal 
any evidence of steatosis or glycogen storage disease, 
but showed evidence of ductular proliferation without 
cholestasis or primary duct injury, reminiscent of the 
response to acute hepatocyte injury (Supplementary 
Fig.  1). 20 mg/m2/day methylprednisolone followed by 
23 mg/m2/day hydrocortisone slightly improved blood 
glucose but rapidly increased body weight and reduced 
growth velocity, leading to cessation after 3  months. 
Subsequent management was with starch-enriched 
feeds during the day and PEG feeding with maltodextrin 
overnight. During nocturnal enteral feeding, glucose 
requirements were around 2–4 mg/kg/min, between 1 and 
5 years of age, and euglycemic clamp studies demonstrated 
a requirement for 2.4 mg glucose/kg/min to maintain 
blood glucose between 4.0 and 4.7 mmol/L at the age 
of 4  years. At 4  years old, she still required continuous 
overnight feeding, and well-documented episodes of 
profound nocturnal hypoglycaemia occurred following 
accidental PEG displacement.
Body length was maintained around −3 s.d. throughout 
childhood except during glucocorticoid treatment. Body 
weight was between 0 and +1.3 s.d., with a weight:length 
ratio above the 97th percentile. Head circumference was 
between +3.0 and +4.0 s.d. (Fig.  2C). IGF1 and IGFBP3 
were low on repeated evaluations, but growth hormone 
(GH) response to arginine stimulation testing at the age 
of 15 months was normal (13.8 μg/L within 30 min). An 
IGF1 generation test (GH 33 µg/kg s.c. daily for 7  days) 
only increased IGF1 from 25 to 56 μg/L. Decreased 
TSH (0.84 mU/L, reference: 0.6–5.5 mU/L) and free T4 
(15.7 pmol/L, reference 10–20 pmol/L) were observed at 
10 months. 1.8 µg/kg/day levothyroxine normalised fT4, 
with TSH remaining low.
Additional problems included severe developmental 
delay and an obstructing Arnold–Chiari malformation 
requiring ventriculoperitoneal shunting at 5  months. 
Recurrent airway infections required intensive respiratory 
support/artificial ventilation; however, no formal 
assessment for immunodeficiency was undertaken. At 
the age of 3.7  years, focal seizures independent from 
hypoglycaemia developed. Levetiracetam was commenced 
and titrated to 50 mg/kg/day at 5 years, when the patient 
Table 1 Summary of clinical syndromic features of patients 1–3.
 Patient 1 Patient 2 Patient 3
Age (years) 5 2 2
Sex Female Male Male
Birth weight (kg) 3.23 (+2.0 s.d.) 4.340 (+6.8 s.d.) 3.98 (+0.33 s.d.)
Birth length (cm) 52 (+1.5 s.d.) 53 (+1.66 s.d.) N/A
Head circumference (cm) 37.5 (+2.3 s.d.) 41 (+5.14 s.d.) N/A
CNS features Megalencephaly Megalencephaly Megalencephaly
 Arnold–Chiari malformation Arnold–Chiari malformation Polymicrogyria
  Polymicrogyria  
 Hydrocephalus Hydrocephalus Hydrocephalus
Seizures Yes Yes Yes
Poly-/syndactyly Yes Yes No
Vascular anomalies Hyperaemia of face Cutis marmorata 
Lower lip angioma
No
 Dorsal haemangioma Head and neck lymphatic 
malformations
 
Developmental delay Yes, severe Yes Yes, severe
Hypotonia Yes Yes Yes
Additional features Diastasis recti Rhizomelia Coarse facial appearance
 Recurrent infections Laryngomalacia  
  Gastroesophageal reflux  
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died following cardiorespiratory arrest during an upper 
airway infection. There was no evidence of hypoglycaemia 
or Arnold–Chiari decompensation. The cause of death 
remains unknown.
Patient 2 (P2) was born to non-consanguineous 
white Spanish parents at term after polyhydramnios, and 
macrocephaly were identified in utero. His birthweight 
was 4340 g (+6.8 s.d.), length 53 cm (+1.66 s.d.) and head 
circumference 41 cm (+5.14 s.d.). Cutis marmorata, lower 
lip hemangioma, cutaneous lymphatic malformations and 
syndactyly in hands and feet were noted at birth. Imaging 
revealed polymicrogyria, hydrocephalus and an Arnold–
Chiari malformation requiring ventriculoperitoneal 
shunting at 12 months. Motor development was delayed 
with marked muscle hypotonia at 10 months. Generalised 
seizures developed at 1 year, treated with sodium valproate. 
Liver ultrasonography at 14 months was normal.
Hypoglycaemia was first noted at 4  days and 
later shown repeatedly to be hypoketotic and 
hypoinsulinaemic. Free fatty acid and acylcarnitine 
profiling were normal, and glucagon stimulation 
demonstrated preserved, mobilisable glycogen stores 
(Table  2). A reduced GH response to hypoglycaemia 
was demonstrated at one-month old, accompanied by 
reduced IGF1 (<25 ng/mL) and IGFBP3 (10th percentile) 
concentrations. Diazoxide had no beneficial effect, and 
management was with regular starch-enriched meals and 
overnight percutaneous feeding. The glucose infusion rate 
used to maintain euglycaemia was 13 mg/kg/min, but no 
formal determination of the minimum requirement was 
undertaken. By 10 months, obesity had developed (weight 
11.3 kg (>2.5 s.d.)). At 12 months, percutaneous feeding 
could be stopped; however, regular carbohydrate-enriched 
meals continue to be required. Although persistently low 
plasma IGF1 and IGFBP3 growth velocity were preserved, 
height remained between the 50th and 75th percentiles at 
2.8 years (target height 20th percentile).
Patient 3 (P3) was born to non-consanguineous 
English parents at 42  weeks gestation following pre-
natal diagnosis of hydrocephalus and macrocephaly. His 
birthweight was 3980 g (+0.33 s.d.). On the first day of life, 
he had a generalized seizure with undetectable plasma 
glucose. Because of recurring hypoglycaemia in the first 
week of life, 13 mg/kg/min intravenous glucose was used 
to maintain euglycaemia without titration to the lowest 
dose required. Repeated evaluations over ensuing months 
showed fasting hypoglycaemia with suppressed ketones, 
undetectable insulin and low but detectable C peptide 
levels (Table 2). Short synacthen testing, thyroid function 
and a genetic screen for congenital hyperinsulinism 
were normal or negative. Diazoxide was trialled with no 
discernible benefit, and 4-hourly carbohydrate-enriched 
feeds were required to maintain euglycaemia.
At 3  months, macrocephaly was noted (head 
circumference 47 cm (+5.49 s.d.)) with a coarse facial 
appearance, hypertrichosis and broad digits with soft 
palms and soles with deep creases and excess skin 
(Fig.  2D, E and F). Imaging showed hydrocephalus and 
bilateral presylvian polymicrogyria requiring insertion 
of a ventriculoperitoneal shunt. A clinical diagnosis 
of MPPH (OMIM #603387 & #615937) was made. At 
2.3 years, weight was 14.7 kg (+1.23 s.d.), height 95.2 cm 
(+1.72 s.d.) and head circumference 53.6 cm (+3.62 s.d.). 
Figure 2
Syndromic features of patients 1 and 3. (A) Image of patient 1 
at one month old demonstrating macrocephaly, facial 
hyperaemia and mildly asymmetric overgrowth. (B) Cutaneous 
syndactyly between the second and third toe on the right foot 
of P1. (C) Image of P1 at age 27 months demonstrating 
macrocephaly, obesity and overgrowth. (D and E) Head and 
facial features of P3 at 27 months showing macrocephaly, 
hypertrichosis, coarse facial appearance. (F) Deep palmar 
creases and excess skin in P3.
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Partial seizures are well controlled on phenobarbital, but 
he is severely intellectually delayed with no speech and 
inability to sit unaided.
Genetic diagnosis
AKT2 was wild type in lymphocyte DNA from P1, 
so the patient and parents underwent whole exome 
sequencing. Five non-synonymous candidate pathogenic 
variants were identified with a frequency <0.01 in 
control databases and a posterior probability of de novo 
inheritance >0.8 (Supplementary Table  1) including a 
single nucleotide substitution (c.2176G > A; p.Glu726Lys) 
in PIK3CA (NM_006218.3), encoding the p110α catalytic 
subunit of PI3K. This variant was called in 26 of 103 
reads, suggesting somatic mosaicism. Sanger sequencing 
identified the mutation in multiple tissues (Fig.  3A), 
while restriction fragment length polymorphism assay 
showed mutation burdens from 24% (saliva) to 42% 
(liver). Dermal fibroblast DNA from P2 was screened for 
mutations in PIK3CA using Sanger sequencing, revealing 
the PIK3CA c.365G > A mutation (p.Gly118Asp). This was 
absent from lymphocyte DNA. Both PIK3CA mutations 
have previously been described (OMIM #602501) 
(16, 24). DNA from a buccal swab of patient P3 was 
screened for overgrowth-associated mutations using an 
Illumina MiSeq Panel (Supplementary Online Materials 
Table  2). A heterozygous c.1117G > A (p.Gly373Arg) 
mutation was identified in PIK3R2 (NM_005027.3), 
encoding the p85β regulatory subunit of class 1A PI3K. 
p.Gly373Arg is the most common mutation in PIK3R2 
associated with MPPH type 1 (OMIM #603387) (16). The 
mutation was identified at a mutation burden of 50%, 
and this was confirmed independently in a diagnostic 
laboratory in lymphocyte DNA, also at 50%, consistent 
with a constitutional mutation. No parental DNA was 
available for testing. The locations of all 3 mutations in 
their respective proteins are schematised in Fig. 3B.
Cellular studies
Dermal fibroblasts of P1 were cultured and shown to 
harbour a mutation burden of 33%, consistent with 
66% of the cells carrying a heterozygous mutation at 
passage 4 (Fig.  3A). They showed a small, significant 
increase in basal phosphorylation of AKT at Threonine 
308/309 and Serine 473/474, as in cells expressing 
AKT2 p.Glu17Lys or the overgrowth-related PIK3CA 
p.His1047Leu (Fig.  4A, B and C). By passage 6, this 
was no longer seen in cells from P1, likely due to 
progressive decline in mutation burden. Seventy-two 
hours exposure to Sirolimus, a dual mTORC1/mTORC2 
inhibitor, did suppress basal hyperphosphorylation of 
AKT at Serine 473/474 (the target site of the upstream 
kinase mTORC2) in early passage cells from another 
patient carrying the same PIK3CA p.Glu726Lys 
Table 2 Representative biochemical profiles of patients 1–3.
 Patient 1 Patient 2 Patient 3 Reference range
Age 9 months 4 days 15 months  
Glucose (mmol/L)* 2.5 2.7 1.9 3.9–5.5
Insulin (pmol/L)* Not detectible Not detectible Not detectible <14
C-peptide (nmol/L)* 0.05 0.2 0.227 <0.166**
Urine ketones* Negative Negative Negative NA
β-Hydroxybutyrate (mmol/L)* 0.024 ND 0.03 >1.8**
Free fatty acids (μmol/L)* 138 ‘Not elevated’ 153 <720**
Cortisol (nmol/L)* 993 464 323 >497
Growth hormone (μg/L)* 7.5 4.7 8.3 >5
Branched chain amino acids Normal Normal Normal N/A
Glucagon stimulation test$ Normal Normal Normal See legend§
Glucose infusion rate to maintain 
euglycaemia (mg/kg/min)
2.4 14$ 13$ >8 in CHI in infancy
Triglyceride (mmol/L) 1.1 1.1 1.0 <1.7
IGF1 (ng/mL) <25 <25 <25 F: 36–170
    M: 27–113
IGFBP3 (µg/mL) 0.9 0.94 0.93 0.8–1.9
Values marked with an asterisk (*) were determined during hypoglycaemia, **cut-offs for differentiation between hypoketotic and physiologic/ketotic 
response to hypoglycaemia. §A normal response to glucagon was defined as a rise in plasma glucose rose by at least 1.7 mmol/L following an 
intramuscular injection of at least 20 μg/kg glucagon. $Glucose infusion rates were not titrated to the minimum requirement.
CHI, congenital hyperinsulinism; ND, not determined.
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mutation (P21) (Fig.  4D), however, or cells expressing 
PIK3CA p.His1047Leu (Fig. 4E).
Metabolic assessment of a wider PI3K-related 
overgrowth spectrum (PROS) cohort
To profile the wider metabolic consequences of mosaic 
activation of PI3K, a further 19 patients with mosaic 
activating PIK3CA mutations were assessed, as summarised 
in Table 3. All patients had clinical disorders encompassed 
by the PIK3CA-Related Overgrowth Spectrum (PROS) (15), 
and were subdivided into those with severe, localized 
overgrowth and those with more diffuse overgrowth 
including the brain, similar to patients 1–3. One further 
patient in this group had the same p.Glu726Lys variant as 
P1 and one had the p.Gly118Asp variant seen in P2.
None of the PROS patients had fasting hypoglycaemia; 
however, three patients with MCAP had low or 
undetectable plasma insulin concentrations with normal 
or low-normal fasting glucose (P19, P20, P22; Table  3). 
One of these patients P19 previously had hypoglycaemia 
during an episode of diarrhoea and vomiting. Five of the 
eight patients with MCAP, including all three with low 
fasting insulin levels, had low IGF1 concentrations. Two 
patients with more extensive overgrowth (P6 and P9) had 
hyperinsulinemia consistent with insulin resistance.
Oral glucose tolerance tests (OGTT) were completed 
for thirteen patients, five with MCAP. As shown in 
Supplementary Fig. 2 and Supplementary Table 3, glucose 
and insulin were within normal ranges. Finally, given the 
large pathological expansion of specific adipose depots in 
many patients with focal severe PROS, and the interest in 
distinct physiological properties and secreted adipokine 
profiles of these depots, adipokine levels relative to whole 
body fat mass were compared between adults in the 
PROS group and a large control dataset (Supplementary 
Fig.  3). However, adipokine levels were similar to those 
in the control population in the large majority of PROS 
patients including those with extreme focal fat mass 
(P7, P8), arguing that the adipokine profiles are not 
distinct in different forms of PROS. Two exceptions were 
P4, a patient with CLOVES who had a disproportionately 
high adiponectin concentration, and P20, a patient 
with CLOVES who had a disproportionately low 
leptin concentration.
Discussion
‘PI3K’ here denotes a group of enzymes composed of one 
of three catalytic subunits (p110α, β or δ) and one of five 
regulatory subunits (p85α, p55α, p50α, p85β or p55γ) 
(25). PI3K generates PIP3 in response to insulin receptor 
Figure 3
Mutations in PI3K-associated genes in 
patients 1–3. (A) Sanger sequencing 
showing de novo PIK3CA c.2176G > A 
mutation in patient 1 at 24–42% in all 
tissues available for DNA testing. 
(B) Schematic showing locations of the 
three PI3 kinase mutations associated 
with hypoglycaemia. p85 BD, p85 binding 
domain; RBD, Ras binding domain; 
SH2/3, SRC homology 2/3; BH, breakpoint 
cluster homologue; P, proline rich domain; 
PH, Phox homology domain.
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Figure 4
Signalling downstream from phosphatidylinositol-3-kinase in dermal fibroblasts from patient 1. AKT phosphorylation at 
Thr308/309 (A) or Ser473/474 (B) was determined by ELISA. Percentages in columns indicate the mutation burden in the cells. 
Data represent pooled, normalised results from three independent experiments plotted as mean ± s.e.m. One-way ANOVA and 
post hoc Dunnett’s test were used to assess significance. Insulin stimulation is shown for illustration only and was excluded from 
this statistical analysis. (C) Immunoblotting for total AKT (1/2/3) from samples used for ELISA (A and B). Representative blot from 
one of three independent replicates. (D and E) AKT Ser473/474 phosphorylation following 72 h of Sirolimus treatment was 
quantified using ELISA and normalised to AKT expression determined by immunoblotting. (D) dermal fibroblasts from P21; 
(E) dermal fibroblasts from P7. Results represent mean ± s.e.m. of three independent replicates. DMSO on its own did not result in 
a change in phosphorylation (data not shown). Statistical analysis was performed as one experiment and separate graphs are 
plotted for clarity only. A two-way ANOVA was performed and followed by a post hoc Dunnett’s test comparing all patients to 
the same control cell line. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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activation, leading in turn to AKT/PKB activation. Genetic 
and pharmacological evidence has established that the 
catalytic p110α subunit, encoded by PIK3CA, is critical 
for the glucose-lowering by insulin, while AKT2 is the 
‘metabolic AKT isoform’ (26). The only example to date of 
hypoketotic hypoglycaemia due to a mutation activating 
insulin signalling is a de novo activating mutation in AKT2 
(27) that has been described in five patients. Activation 
of other components of this pathway, such as PI3K, 
would be anticipated to cause a similar metabolic profile; 
however, given the pleiotropic growth-promoting actions 
of PI3K, the associated syndrome would be expected to 
be more complex. Mosaic genetic activation of PI3K has 
recently been described in a wide range of segmental 
overgrowth disorders with overlapping features (13, 28). 
Seven patients with PIK3CA mutations, overgrowth 
and infantile hypoglycaemia were described while 
this work was underway (18), but no further metabolic 
characterisation was undertaken.
We describe three patients with megalencephalic 
PI3K-related overgrowth who had severe, likely non-
insulin-dependent hypoketotic hypoglycaemia, similar 
to that caused by activating AKT2 mutations, persisting 
to at least 2  years old in all cases. This affected only a 
subset of patients with PI3K-related overgrowth, likely 
due to the predominantly mosaic nature of the condition. 
This mosaicism, with only some cells and tissues affected, 
complicates efforts to distinguish among several possible 
mechanisms underlying hypoglycaemia. The simplest 
explanation is that tonic activity of hepatic PI3K leads 
to inappropriate suppression of hepatic glycogenolysis 
and gluconeogenesis in the postabsorptive state. Most of 
the liver would have to be affected to exert a significant 
effect. A liver biopsy from P1 presented the opportunity 
to examine liver in one patient with PIK3CA-related 
hypoglycaemia. It showed a mutation burden of 42%, 
corresponding to 84% of cells bearing a heterozygous 
mutation; however, neither glycogenosis nor steatosis 
Table 3 Genetic diagnosis and biochemical profile following an overnight fast in patients with PROS.
 
 
ID
 
 
Sex
 
Age 
(years)
 
 
Syndrome
 
Site of 
overgrowth
B.M.I.  
(kg/m2) or 
*Z-score
Fat 
mass 
(%)
 
PIK3CA 
mutation
 
Glucose 
(mmol/L)
 
Insulin 
(pmol/L)
HbA1c 
(mmol/
mol)
 
Adiponectin 
(mg/L)
 
Leptin 
(μg/L)
 
IGF1  
(ng/mL)
NR        3.9–5.5 0–60 30–48 See  
legend
See 
legend
See 
legend
P4 M 48 CLOVES L foot 26.7 13 C420R 4 11 40 23.2 ND 76
P5 M 29 CLOVES L leg and 
trunk
25.7 23 E545K 4.5 27 34 3.8 5.7 163
P6 M 15 CLOVES R thorax −1.6* 19 E542K 6.2 165 ND 17.3 1.8 119
P7 F 37 FAH Both legs 55 54 H1047L 3.9 13 36 16.9 166 141
P8 F 31 FAH R arm 32.5 46 H1047L 4.7 ND ND ND ND 221
P9 F 34 FAH L leg 32.7 47 H1047R 4.7 217 43 1.5 45.5 141
P10 F 9 FAH L leg >+3* 29 H1047R 4.8 42 36 ND ND 122
P11 F 22 MO Both arms 21.9 32 H1047R 4.7 31 ND 6.3 6.6 242
P12 M 34 KTS L leg 27.8 38 V346insK 4.3 29 38 ND 16 168
P13 F 40 MD L hand 32.8 57 H1047R 4.5 73 37 ND ND ND
P14 F 39 MD 2 R fingers 25 40 M1043_
N1044delinsIY
4.7 41 33 7.4 13.5 176
P15 F 35 MCAP Diffuse 34.9 38 G118D 5.1 31 40 5.1 33.3 145
P16 M 29 MCAP Diffuse 27.1 23 E81K 5.2 31 38 3.9 4.1 158
P17 F 18 MCAP Diffuse 23.6 43 E81K 5.1 80 35 8.6 31.4 382
P18 F 21 MCAP Diffuse 43 52 G914R 5.4 51 36 5.1 ND 85
P19 M 1.5 MCAP Diffuse ND ND R88Q 5.1 <3 48 ND ND <25
P20 M 21 MCAP Diffuse 23.9 44 E726K 3.9 7 ND 6.6 2 28
P21 M 3 MCAP Diffuse +1* 43 R93Q 4.3 18 ND ND ND 60
P22 M 12 MCAP Diffuse ND ND D350G 3.9 <14 ND ND ND 80
BMI-specific reference ranges for adiponectin in females—<25 kg/m2: 4.4–17.7 mg/mL; 30–35 kg/m2: 2.6–14.9 mg/mL; >35 kg/m2: 2.6–17.1 mg/mL. 
Adiponectin reference in males—<25 kg/m2: 2.6–12.6 mg/mL; 25–30 kg/m2: 2.4–10.6 mg/mL. BMI-specific reference ranges for leptin in  
females—<25 kg/m2: 2.4–24.4 ng/mL; 25–30 kg/m2: 8.6–38.9 ng/mL; >35 kg/m2: 22.7–113.6 ng/mL. Leptin reference in males—<25 kg/m2: 0.4–8.3 ng/mL; 
25–30 kg/m2: 1.5–13.0 ng/mL. Age-specific IGF-1 references ranges in females—9–11 years: 87–396 ng/mL; 16–20 years: 266–467 ng/mL; 21–24 years: 
148–330 ng/mL; 25–40 years: 123–304 ng/mL. IGF-1 reference ranges in males—2–60 months: 27–113 ng/mL; 12–15 years: 115–495 ng/mL; 21–24 years: 
186–397 ng/mL; 25–40 years: 124–300 ng/mL; 41–50 years: 89–239 ng/mL.
CLOVES, congenital lipomatous overgrowth with vascular, epidermal and skeletal anomalies; FAH, fibroadipose hyperplasia; KTS, Klippel–Trenaunay 
syndrome; MCAP, macrocephaly and capillary malformation syndrome; MD, macrodactyly; MO, muscle overgrowth; ND, not determined; 
NR, normal range.
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were seen, while prominent ductular reaction without 
cholestasis or primary duct injury was reminiscent of 
the response to severe and acute hepatocyte injury (29). 
Without knowing which cells harboured the PIK3CA 
mutation, no more precise correlation was possible 
between the abnormal histology and the mutation. If 
liver-autonomous failure to derepress glycogenolysis/
gluconeogenesis were the major abnormality explaining 
PROS-related hypoglycaemia, then only a small glucose 
requirement to maintain euglycaemia would be expected, 
as reported for patients with activating AKT2 mutations. 
(27) This was confirmed for P1 in this report; however, 
infusion rates in P2 and P3 were reported to be high. 
Whether glucose infusions were titrated to the lowest 
possible rate to maintain euglycaemia was unclear, 
however.
PI3K-related hypoglycaemia may alternatively reflect 
suppression of adipose lipolysis, which provides energy 
and gluconeogenic substrates to fasting hepatocytes 
(30, 31). This was shown by the lack of an adequate rise of 
free fatty acids in P1 during hypoglycaemia (Table 2). Fasting 
free fatty acid levels in the PROS cohort were not studied; 
however, in two patients with genetic AKT2 activation, 
we observed correlation of free fatty acid suppression with 
fasting hypoglycaemia (32). Although increased PI3K-
mediated, GLUT4-dependent glucose uptake into skeletal 
muscle and adipose tissue could also cause hypoglycaemia, 
patients with severe local adipose or muscle overgrowth 
due to strongly activating PIK3CA mutations, but with 
no liver involvement, exhibited neither spontaneous 
hypoglycaemia nor hypoinsulinaemia. This argues that 
regional adipose tissue or muscle PI3K-mediated glucose 
uptake either does not occur, or is insufficient to produce 
hypoglycaemia.
Finally, aberrant activity of PI3K in the brain may also 
play a role: low IGF1 levels in 63% of the MCAP patients 
suggest dysfunctional GH secretion or action. This may 
reflect tonically active PI3K in the hypothalamus and/or 
the pituitary, mimicking IGF1 action and erroneously 
activating negative feedback inhibition of GH-releasing 
hormone or GH release. In contrast, stimulation of GH 
secretion on provocative testing may yield normal results, 
as shown in P1, suggesting that suppressed basal secretion 
may be overridden. The central hypothyroidism in P2, 
and in three previously described MCAP patients (18), and 
the modest GH and cortisol responses to hypoglycaemia 
suggest that hypothalamic–pituitary function may 
show wider perturbation. Attenuated neuroendocrine 
counterregulatory responses to hypoglycaemia are a 
plausible explanation for the GH and cortisol responses; 
however, this cannot be proven, and studies of further 
affected patients will be required to elucidate whether 
abnormality of regulation, a subtle developmental disorder 
of the hypothalamus/pituitary or both are seen in MCAP 
caused by PI3K activation. Evidence that different adipose 
depots show distinct profiles of adipokine secretion 
(33, 34) raised the possibility that pathological expansion 
of only some adipose depots (e.g. legs vs upper body) would 
correspond to a distinct pattern of circulating adipokines. 
In general, we found this not to be the case, with the large 
majority of patients showing a similar relationship between 
adipokine concentrations and whole body adipose tissue 
mass to that seen in the general population. Two outliers 
were found with perturbed adiponectin or leptin levels; 
however, the explanation was not immediately clear, and 
wider investigation may be warranted.
Importantly, our findings suggest that mTOR 
inhibitors such as Sirolimus may have therapeutic 
benefit instead of, or in addition to, nutritional therapies 
including percutaneous overnight feeding. Although 
Sirolimus is primarily an mTORC1 inhibitor, prolonged 
use sequesters components of the mTORC2 complex (35), 
which acts upstream from AKT in insulin signalling. Our 
findings suggest that Sirolimus at very low doses (1.1–
2.2 ng/mL) may be sufficient, unlike the high doses used 
in hyperinsulinism (5–15 ng/mL) (36). In future, low doses 
of more specific class 1A PI3K inhibitors, many examples 
of which are in clinical trials for cancer, may offer a more 
specific targeted therapy.
In conclusion, we report that a subset of patients 
with diffuse, megalencephalic forms of PIK3CA-related 
segmental overgrowth and MPPH exhibit severe insulin-
independent hypoketotic hypoglycaemia. This metabolic 
phenocopy of hypoglycaemia driven by genetic AKT2 
activation is not seen in patients with extreme regional 
adipose or muscular overgrowth associated with ‘hot 
spot’ activating PIK3CA mutations, suggesting that 
diffuse mutation carriage is more important than the 
degree of PI3K activation in determining the phenotype. 
We suggest that endocrinologists should be alert to the 
possibility of syndromic PI3K-related overgrowth when 
evaluating infants with hypoinsulinaemic hypoketotic 
hypoglycaemia, or with equivocal biochemical testing 
for congenital hyperinsulinism, and that they should 
understand the challenges of testing for a mosaic genetic 
disorder. Prior knowledge and our cellular studies suggest 
that mTOR inhibitors may offer therapeutic benefit, and 
are worthy of clinical study.
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This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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